MD Anderson to Validate First-Line Treatment for Early-Stage Follicular Lymphoma with Phase 3 Rituxan Combination Trial
Clinical Design and Progress
NCT01473628, led by MD Anderson Cancer Center, is a randomized Phase 3 study comparing local radiation therapy alone versus rituximab in combination for patients with Stage 1-2, Grade 1-2 follicular lymphoma. Initiated in May 2013, the study is currently active and in the recruitment phase, with an expected completion date of May 2027. The primary objective is to determine if adding systemic B-cell depletion to the high local control achieved with radiation alone can reduce recurrence and disease progression outside the radiation field.
Drug and Mechanism of Action
The investigational drug is Rituxan/MabThera (rituximab), a chimeric monoclonal antibody targeting CD20 on B-cells. It eliminates normal and malignant CD20-positive B-cells through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. The rationale for combination therapy is that while radiation directly controls the lesion, rituximab can suppress microscopic systemic disease not visualized on imaging. This represents a treatment intensification strategy aimed at extending progression-free survival (PFS) without adding cytotoxic chemotherapy.
Standard of Care and Competitive Landscape
In limited-stage follicular lymphoma, 24 Gy of local radiation therapy is a standard treatment for curative intent, with observation, rituximab alone, or radiation combined with R-CVP used depending on patient characteristics. Randomized studies have compared radiation alone with radiation and R-CVP. Current competitive studies include a comparison of 24 Gy radiation and rituximab versus 4 Gy radiation and obinutuzumab (CD20). Therefore, NCT01473628 differentiates itself by evaluating whether adding only rituximab to a classic 24 Gy-based regimen can limit toxicity while reducing systemic recurrence.
Regulatory and Market Implications
Rituxan was developed by Genentech and commercialized by Roche Holding, and the FDA initially approved it on November 26, 1997, for relapsed or refractory low-grade or follicular CD20-positive B-cell non-Hodgkin's lymphoma. In Europe, MabThera was approved on June 2, 1998, and in Japan, it was approved in June 2001 for CD20-positive low-grade/follicular B-cell lymphoma, among other indications. FDA records indicate that instead of an AdComm vote, the Biologics License Application (BLA) approval action was taken. This study is a post-approval clinical trial that expands the evidence base for the use of an already approved antibody in earlier stages. The global follicular lymphoma treatment market was valued at USD 2.08 billion in 2024, and positive PFS results could influence the use of rituximab, including biosimilars, and treatment guidelines for early-stage disease.
This Phase 3 trial evaluates whether adding the marketed CD20 antibody rituximab to the 24 Gy radiation standard of care improves progression-free survival in limited-stage follicular lymphoma. In the short term, the key catalyst is the study completion and data release expected in May 2027, and positive results could shift treatment paradigms from observation or radiation alone to combination therapy. In the medium to long term, the findings could expand the use of rituximab, including biosimilars such as Celltrion's Truxima, in the USD 2.08 billion global market. For researchers and clinicians, the study provides evidence for systemic recurrence control without chemotherapy, compared to radiation-R-CVP and 4 Gy radiation-obinutuzumab strategies, but mature PFS and long-term toxicity data are prerequisites for changes in treatment guidelines.
Source: ClinicalTrials.gov (api_ct)